Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes

Biochemical Pharmacology

Volumn 68, Issue 4, 2004, Pages 773-782

  Piver, Bertrand ^a   Fer, Maude ^a   Vitrac, Xavier ^b   Merillon, Jean Michel ^b   Dreano, Yvonne ^a   Berthou, François ^a   Lucas, Danièle ^a  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

CYP; CYP1A1; CYP1A2; CYP1B1; cytochrome P450; Cytochrome P450; EROD; ethoxyresorufin O deethylase; Piceatannol; Trans resveratrol

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; FURAFYLLINE; MONOCLONAL ANTIBODY; PHENACETIN; PICEATANNOL; RECOMBINANT PROTEIN; RESORUFIN; RESVERATROL; STILBENE DERIVATIVE;

ARTICLE; CATALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; METABOLIC RATE; PRIORITY JOURNAL;

ANTIOXIDANTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; HUMANS; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS; STILBENES;

EID: 3242676024     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.05.008     Document Type: Article

References (31)

1. Soleas G.J., Diamandis E.P., Golberg D.M. Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal. 11:1997;287-313
2. Fauconneau B., Waffo-Teguo P., Huguet F., Barrier L., Decendit A., Merillon J.M. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from vitis vinifera cell cultures using in vitro tests. Life Sci. 61:1997;2103-2110
3. Frankel E.N., Waterhouse A.L., Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet. 341:1993;1103-1104
4. Bertelli A.A.E., Giovanni L., Stradi R., Urien S., Tillement J.P., Bertelli A. Kinetics of trans- and cis-resveratrol (3,4′,5- trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res. 26:1996;77-81
5. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:1997;218-220
6. Ciolino H.P., Daschner P.J., Yeh G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 58:1998;5707-5712
7. Ciolino H.P., Yeh G.C. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP 1A1 expression by resveratrol. Mol Pharmacol. 56:1999;760-767
8. Chun Y.J., Kim M.Y., Guengerich F.P. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun. 262:1999;20-24
9. Chang T.K., Lee W.B., Ko H.H. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can J Physiol Pharmacol. 78:2000;874-881
10. Chang T.K., Chen J., Lee W.B. Differential inhibition and inactivation of human CYP1 enzymes by trans- resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 299:2001;874-882
11. Yu C., Shin Y.G., Kosmeder J.W., Pezzuto J.M., van Breemen R.B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom. 17:2003;307-313
12. Chan W.K., Delucchi A.B. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci. 67:2000;3103-3112
13. Piver B., Berthou F., Dreano Y., Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non-volatile red wine components. Toxicol Lett. 125:2001;83-91
14. Potter G.A., Patterson L.H., Wanogho E., Perry P.J., Butler P.C., Ijaz T., et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer. 86:2002;774-778
15. Yu C., Shin Y.G., Chow A., Li Y., Kosmeder J.W., Lee Y.S., et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res. 19:2002;1907-1914
16. Vitrac X., Krisa S., Decendit A., Vercauteren J., Nührich A., Monti J.P., et al. Carbon 14-labelling of wine polyphenols in Vitis vinifera cell suspension cultures. J Biotech. 95:2002;49-56
17. Berthou F., Flinois J.P., Ratanasavanh D., Beaune P., Riche C., Guillouzo A. Evidence for the involvement of several cytochromes P450 in the first step of caffeine metabolism by human liver microsomes. Drug Metab Dispos. 19:1991;561-567
18. Burke M.D., Thomson S., Elcombe C.R., Halpert J., Haaparanta T., Mayer R.T. Ethoxy-, pentoxy- and benzyloxyphenoxaxones and homologues: a series of substrates distinguish between different induced cytochromes P-450. Biochem Pharmacol. 34:1985;33-37
19. Laemli V.K. Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685
20. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA/Phys Sci. 76:1979;4350-4354
21. Kunze K.L., Trager W.F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol. 6:1993;649-656
22. Williams M.L., Lennard M.S., Martin I.J., Tucker G.T. Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis. 15:1994;2733-2738
23. Chang T.K., Chen J., Pillay V., Ho J.Y., Bandiera S.M. Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol Sci. 71:2003;11-19
24. Guengerich F.P., Shimada T. Activation of procarcinogens by human cytochromes P450 enzymes. Mutat Res. 400:1998;201-213
25. Yang C.S., Smith T.J., Hong J.Y. Cytochromes P450 enzymes as targets for chemoprevention against chemical carcinogenesis and toxicity opportunities and limitations. Cancer Res. 54(Suppl):1994;1982-1986
26. Andlauer W., Kolb J., Siebert K., Furst P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res. 26:2000;47-55
27. Kuhnle G., Spencer J.P., Chowrimootoo G., Schroeter H., Debnam E.S., Srai S.K., et al. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun. 272:2000;212-217
28. De Santi C., Pietrabissa A., Spisni R., Mosca F., Pacifici G.M. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica. 30:2000;857-866
29. Gill M.T., Bajaj R., Chang C.J., Nichols D.E., McLaughlin J.L. 3,3′,5′-tri-O-methylpiceatannol: improvements over piceatannol in bioactivity. J Nat Prod. 50:1987;36-40
30. Chang T.K., Yeung R.K. Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can J Physiol Pharmacol. 79:2001;220-226
31. Lu J., Ho C., Ghai G., Chen K.J. Resveratrol analogue 3,4,5,4′-tetrahydroxystilbene differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis. 22:2001;321-328